

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: [ICC International Cannabis Corp.](#) (the "Issuer").

Trading Symbol: [WRLD.U](#)

Number of Outstanding Listed Securities: [706,105,955](#) as of [November 30, 2019](#).

Date: [December 3, 2019](#) (for the month of **November 2019**)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

[The Issuer continues to evaluate potential marijuana projects and cannabis related companies for potential acquisition and growth. The Issuer continues to concentrate on assembling a robust portfolio of licences globally specializing in the cultivation, extraction and distribution of medical cannabis and CBD products with a specific emphasis on both the European Union and Latin American](#)

regions, and a keen interest in Africa and Australasia, Southeast Asia, and the Pacific Rim.

2. Provide a general overview and discussion of the activities of management.

During the month of **November 2019**, the Issuer:

- Announced that it agreed to terminate the transactions relating to the purchase of Wayland Group Corp.'s international portfolio of cannabis assets, licenses and operations pursuant to a termination agreement.
  - Announced that it is pursuing a cannabis tolling agreement with Wayland Group Corp.
  - Tended to general management and administrative matters.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable to the Issuer for the month of **November 2019**.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable to the Issuer for the month of **November 2019**.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On **November 13, 2019** the Issuer announced that the Issuer and Wayland Group Corp ("Wayland") are pursuing a cannabis tolling agreement (the "Tolling Agreement"), whereby Wayland will process cannabis produced by the Issuer or its affiliates at Wayland's licensed, EU-GMP facilities in Langton, Ontario and Dresden, Germany. Additional details regarding the proposed Tolling Agreement will be provided once a definitive agreement has been entered into between both parties.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

On **November 13, 2019**, the Issuer announced that it agreed to terminate the transactions relating to the purchase of Wayland's international portfolio of cannabis assets, licenses and operations pursuant to a termination agreement dated October 11, 2019 (the "Termination Agreement"). Pursuant to the Termination Agreement, ICC will relinquish its right to acquire Wayland's international asset portfolio and Wayland will return the 246,613,995 common

shares in the capital of ICC it previously received pursuant to the definitive agreement between both parties dated April 22, 2019. The Termination Agreement also provides that Wayland will retain certain assets previously transferred from Wayland to ICC, together with a mutual release.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable to the Issuer for the month of **November 2019**.

8. Describe the acquisition of new customers or loss of customers.

Not applicable to the Issuer for the month of **November 2019**.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable to the Issuer for the month of **November 2019**.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable to the Issuer for the month of **November 2019**.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable to the Issuer for the month of **November 2019**.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable to the Issuer for the month of **November 2019**.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable to the Issuer for the month of **November 2019**.

14. Provide details of any securities issued and options or warrants granted.

Not applicable to the Issuer for the month of **November 2019**.

15. Provide details of any loans to or by Related Persons.

Not applicable to the Issuer for the month of **November 2019**.

16. Provide details of any changes in directors, officers or committee members.

Not applicable to the Issuer for the month of **November 2019**.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion & Analysis dated August 31, 2019 (the "MD&A"). The MD&A is available on the Issuer's SEDAR profile at [www.sedar.com](http://www.sedar.com).

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 3, 2019.

Eugene Beukman  
Name of Director or Senior  
Officer

"Eugene Beukman"  
Signature

Director  
Official Capacity

<b>Issuer Details</b>		For Month	Date of Report
Name of Issuer	End	YY/MM/DD	
<b>ICC International Cannabis Corp</b>	<b>November</b>	<b>19/12/03</b>	
	<b>2019</b>		
Issuer Address			
<b>810 – 789 West Pender Street</b>			
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.	
<b>Vancouver, BC V6C 1H2</b>	<b>604-687-3141</b>	<b>604-687-2308</b>	
Contact Name	Contact Position	Contact Telephone No.	
<b>Eugene Beukman</b>	<b>Director</b>	<b>604-782-4191</b>	
Contact Email Address	Web Site Address		
<b>ebeukman@pendergroup.ca</b>	<b>N/A</b>		